Kyla Driscoll

1.6k total citations · 1 hit paper
17 papers, 994 citations indexed

About

Kyla Driscoll is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Kyla Driscoll has authored 17 papers receiving a total of 994 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 7 papers in Molecular Biology and 6 papers in Immunology. Recurrent topics in Kyla Driscoll's work include Pancreatic and Hepatic Oncology Research (6 papers), TGF-β signaling in diseases (6 papers) and Cancer Immunotherapy and Biomarkers (4 papers). Kyla Driscoll is often cited by papers focused on Pancreatic and Hepatic Oncology Research (6 papers), TGF-β signaling in diseases (6 papers) and Cancer Immunotherapy and Biomarkers (4 papers). Kyla Driscoll collaborates with scholars based in United States, Germany and United Kingdom. Kyla Driscoll's co-authors include Karim A. Benhadji, Ivelina Gueorguieva, Shawn T. Estrem, Ann Cleverly, Christopher A. Slapak, Michael Lahn, Susan C. Guba, Stephan Herbertz, Anja J. Stauber and David Schaer and has published in prestigious journals such as Journal of Biological Chemistry, Cancer Research and Cancers.

In The Last Decade

Kyla Driscoll

17 papers receiving 981 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway

2015 453 citations Michael Lahn, Stephan Herbertz et al. Drug Design Development and Therapy profile →

Peers

Kyla Driscoll

ONCOL

MB

IMMUN

CR

PRM

Rindert Missiaen United States

Arnaud Jabouille France

Stephen P. Santoro United States

Ece Kadioglu Switzerland

Ik Sun Kim United States

Mark J.A. Schoonderwoerd Netherlands

Amit Goldstein United States

Federico Sandoval France

Martina Schmittnaegel Switzerland

Pavan Bachireddy United States

Rindert Missiaen United States

Kyla Driscoll

449 ×0.7

ONCOL

432 ×1.0

MB

336 ×1.1

IMMUN

265 ×1.5

CR

155 ×1.3

PRM

Citations per year, relative to Kyla Driscoll Kyla Driscoll (= 1×) peers Rindert Missiaen

Countries citing papers authored by Kyla Driscoll

Since Specialization

Citations

This map shows the geographic impact of Kyla Driscoll's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kyla Driscoll with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kyla Driscoll more than expected).

Fields of papers citing papers by Kyla Driscoll

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kyla Driscoll. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kyla Driscoll. The network helps show where Kyla Driscoll may publish in the future.

Co-authorship network of co-authors of Kyla Driscoll

This figure shows the co-authorship network connecting the top 25 collaborators of Kyla Driscoll. A scholar is included among the top collaborators of Kyla Driscoll based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kyla Driscoll. Kyla Driscoll is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

1.

Sagar, Divya, Kevin C. Lindquist, Qianxu Guo, et al.. (2024). Abstract 1872: A next generation treatment for Nectin-4 positive cancers - Preclinical characterization of LY4052031, an anti-Nectin-4 antibody, conjugated to a novel camptothecin payload. Cancer Research. 84(6_Supplement). 1872–1872. 2 indexed citations

2.

Vathiotis, Ioannis, Jon Zugazagoitia, Konstantinos N. Syrigos, et al.. (2021). Quantitative Assessment of CD200 and CD200R Expression in Lung Cancer. Cancers. 13(5). 1024–1024. 8 indexed citations

3.

Vathiotis, Ioannis, Saba Shafi, Thazin Nwe Aung, et al.. (2021). Multiplex Quantitative Analysis of Tumor-Infiltrating Lymphocytes, Cancer-Associated Fibroblasts, and CD200 in Pancreatic Cancer. Cancers. 13(21). 5501–5501. 14 indexed citations

4.

González‐López, Olga, Hye Jin Shin, Kyla Driscoll, et al.. (2019). A herpesvirus transactivator and cellular POU proteins extensively regulate DNA binding of the host Notch signaling protein RBP-Jκ to the virus genome. Journal of Biological Chemistry. 294(35). 13073–13092. 5 indexed citations

5.

Melisi, Davide, Rocio García‐Carbonero, Teresa Macarulla, et al.. (2019). TGFβ receptor inhibitor galunisertib is linked to inflammation- and remodeling-related proteins in patients with pancreatic cancer. Cancer Chemotherapy and Pharmacology. 83(5). 975–991. 77 indexed citations

6.

Haidar, Jaafar N., Stephen Antonysamy, Sneha Mathew, et al.. (2019). Abstract 2753: The molecular basis of blocking the TIM-3 checkpoint with the LY3321367 mAb in cancer immunotherapy. Cancer Research. 79(13_Supplement). 2753–2753. 6 indexed citations

7.

Haidar, Jaafar N., Stephen Antonysamy, Sneha Mathew, et al.. (2019). Abstract 2753: The molecular basis of blocking the TIM-3 checkpoint with the LY3321367 mAb in cancer immunotherapy. 1 indexed citations

8.

Holmgaard, Rikke, David Schaer, Yanxia Li, et al.. (2018). Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade. Journal for ImmunoTherapy of Cancer. 6(1). 47–47. 267 indexed citations

9.

Gonzàlez-Juncà, Alba, Kyla Driscoll, Ilenia Pellicciotta, et al.. (2018). Autocrine TGFβ Is a Survival Factor for Monocytes and Drives Immunosuppressive Lineage Commitment. Cancer Immunology Research. 7(2). 306–320. 66 indexed citations

10.

Witcher, Derrick R., Anja Köester, Jinsam You, et al.. (2018). FcγRIIIa-dependent IFN-γ release in whole blood assay is predictive of therapeutic IgG1 antibodies safety. mAbs. 10(6). 913–921. 8 indexed citations

11.

Huang, Huocong, et al.. (2018). Abstract B68: Targeted inhibition of Tgfβr2 reduces IL-6 production from cancer-associated fibroblasts, suppresses Stat3 activation in pancreatic cancer cells and reverses immunosuppression. Cancer Immunology Research. 6(9_Supplement). B68–B68. 1 indexed citations

12.

Tolcher, Anthony W., Jordan Berlin, Jan Cosaert, et al.. (2017). A phase 1 study of anti-TGFβ receptor type-II monoclonal antibody LY3022859 in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 79(4). 673–680. 80 indexed citations

13.

Dempsey, Jack, Lysiane Huber, Amélie Forest, et al.. (2017). Abstract 583: The CDK4/6 inhibitor abemaciclib induces synergistic immune activation and antitumor efficacy in combination with PD-L1 blockade. Cancer Research. 77(13_Supplement). 583–583. 2 indexed citations

14.

Schaer, David & Kyla Driscoll. (2016). Abstract 1415: Targeting the TGFβ pathway with galunisertib, a small molecule inhibitor of TGFβRI, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint inhibition. Cancer Research. 76(14_Supplement). 1415–1415. 2 indexed citations

15.

Schaer, David, Yanxia Li, Stephen Castaneda, et al.. (2016). Abstract A091: Targeting the TGFb pathway with galunisertib, a TGFbRI SMI, promotes antitumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint inhibition. Cancer Immunology Research. 4(1_Supplement). A091–A091. 1 indexed citations

16.

Schaer, David, Yanxia Li, Stephen Castaneda, et al.. (2015). Targeting the TGFβ pathway with galunisertib, a TGFβRI SMI, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint inhibition. Journal for ImmunoTherapy of Cancer. 3(Suppl 2). P402–P402. 1 indexed citations

17.

Lahn, Michael, Stephan Herbertz, Anja J. Stauber, et al.. (2015). Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway. Drug Design Development and Therapy. 4479–4479. 453 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact